Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2015-07, Vol.15 (1), p.71-71, Article 71
Main Authors: Alfarouk, Khalid O, Stock, Christian-Martin, Taylor, Sophie, Walsh, Megan, Muddathir, Abdel Khalig, Verduzco, Daniel, Bashir, Adil H H, Mohammed, Osama Y, Elhassan, Gamal O, Harguindey, Salvador, Reshkin, Stephan J, Ibrahim, Muntaser E, Rauch, Cyril
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-015-0221-1